Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the long-term efficacy and safety of zolpidem-MR [modified release] 12.5 mg compared to placebo, when both are administered over a long-term period 'as needed', in patients with chronic primary insomnia

Next Previous
Trial Profile

Evaluation of the long-term efficacy and safety of zolpidem-MR [modified release] 12.5 mg compared to placebo, when both are administered over a long-term period 'as needed', in patients with chronic primary insomnia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2009

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zolpidem (Primary)
  • Indications Insomnia
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ZOLONG
  • Sponsors Sanofi

    • Most Recent Events

    • 08 Apr 2009 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
    • 29 Jun 2007 Results have been reported.
    • 15 Feb 2007 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top